SEC Form 4 · accession 0001209191-17-052183
MAGELLAN HEALTH INC · MGLN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mostafa Kamal
Officer — CEO, Magellan Rx Management
Period of report
Sep 8, 2017
Accepted (ET)
Sep 11, 2017 · 12:47 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000019411
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Common Stock, $0.01 par value | Sep 8, 2017 | X | 6,267 | $60.55 | A | 6,267 | D | |
| Ordinary Common Stock, $0.01 par valueF2 | Sep 8, 2017 | S | 6,267 | $81.5252 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F4,F3 | $60.55 | Sep 8, 2017 | X | 6,267 | D | — | Aug 3, 2025 | Common Stock | 6,267 | 41,700 | D |
Explanation of responses
- F1This transaction was effectuated pursuant to a Rule 10b-5-1 Plan.
- F2The number of securities reported represents an aggregate number of shares sold in multiple open market transactions at prices ranging from $81.00 to $81.90, inclusive. The price reported represents the weighted average price. The Reporting Person undertakes to provide staff of the SEC, the issuer, or a stockholder of the issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.
- F3Of the 41,700 stock options remaining in this tranche, 26,066 are currently vested and available. The remainder of 16,667 options shall vest on August 3, 2018.
- F4Not applicable.